Etamicastat (INNTooltip International Nonproprietary Name; developmental code name BIA 5-453) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which was under development for the treatment of hypertension (high blood pressure) and heart failure but was never marketed.

[1][2] The peripheral selectivity of etamicastat is in contrast to the earlier DBH inhibitor nepicastat, which is centrally active and produced associated side effects.

[2] Etamicastat was found to reduce blood pressure but not affect heart rate in clinical trials.

[2] The development of etamicastat was discontinued by August 2016.

This antihypertensive-related article is a stub.